Abstract
Opioid analgesics are the most frequently prescribed medications for the treatment of moderate or severe pain; however, their use is constrained by unwanted side effects. One therapeutic approach used to improve the side effect profile of opioids is the administration of a second drug in an opioid-containing mixture. Preclinical studies designed to predict the therapeutic potential of novel opioid-containing drug combinations are currently underway, and must rely on quantitative methods to assess their interactive effects. In this manuscript, an overview of isobolographic analysis is presented along with recent advances in isobolographic theory pertaining to drugs that differ in efficacy and to the statistical analysis of dose-addition. Next, studies using these analyses to assess the interactive effects of opioids and novel adjunct drugs, including selective COX-2 inhibitors, α2-adrenergic receptor agonists, δopioids, glutamate receptor antagonists and cannabinoid receptor agonists, are reviewed. Finally, comments on the future assessment of drug combinations for the treatment of pain-related disorders are made.
Keywords: Drug combination, isobologram, dose-addition, pain, opioid, analgesia, NSAID, ALpha2ARs, NMDAR
CNS & Neurological Disorders - Drug Targets
Title: Preclinical Assessment of Drug Combinations for the Treatment of Pain: Isobolographic and Dose-Addition Analysis of the Opioidergic System
Volume: 10 Issue: 5
Author(s): Bradford D. Fischer
Affiliation:
Keywords: Drug combination, isobologram, dose-addition, pain, opioid, analgesia, NSAID, ALpha2ARs, NMDAR
Abstract: Opioid analgesics are the most frequently prescribed medications for the treatment of moderate or severe pain; however, their use is constrained by unwanted side effects. One therapeutic approach used to improve the side effect profile of opioids is the administration of a second drug in an opioid-containing mixture. Preclinical studies designed to predict the therapeutic potential of novel opioid-containing drug combinations are currently underway, and must rely on quantitative methods to assess their interactive effects. In this manuscript, an overview of isobolographic analysis is presented along with recent advances in isobolographic theory pertaining to drugs that differ in efficacy and to the statistical analysis of dose-addition. Next, studies using these analyses to assess the interactive effects of opioids and novel adjunct drugs, including selective COX-2 inhibitors, α2-adrenergic receptor agonists, δopioids, glutamate receptor antagonists and cannabinoid receptor agonists, are reviewed. Finally, comments on the future assessment of drug combinations for the treatment of pain-related disorders are made.
Export Options
About this article
Cite this article as:
D. Fischer Bradford, Preclinical Assessment of Drug Combinations for the Treatment of Pain: Isobolographic and Dose-Addition Analysis of the Opioidergic System, CNS & Neurological Disorders - Drug Targets 2011; 10 (5) . https://dx.doi.org/10.2174/187152711796235050
DOI https://dx.doi.org/10.2174/187152711796235050 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
From the Prodrome to Chronic Schizophrenia: The Neurobiology Underlying Psychotic Symptoms and Cognitive Impairments
Current Pharmaceutical Design MicroRNA Landscape in Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Neuroprotection of Rotenone-Induced Parkinsonism by Ursolic Acid in PD Mouse Model
CNS & Neurological Disorders - Drug Targets Effects of Yokukansan, a Japanese Kampo Medicine for Symptoms Associated Autism Spectrum Disorder
CNS & Neurological Disorders - Drug Targets Is Plasma Amyloid-β a Reliable Biomarker for Alzheimers Disease?
Recent Patents on CNS Drug Discovery (Discontinued) Formulation Strategies of Nano Lipid Carrier for Effective Brain Targeting of Anti-AD Drugs
Current Pharmaceutical Design The Summary of the Scale and the Methods to Inhibit and Remove Scale Formation in the Oil Well and the Gathering Line
Recent Patents on Chemical Engineering Biological Function and Mechanism of Bone Marrow Mesenchymal Stem Cells-packed Poly (3,4-ethylenedioxythiophene) (PEDOT) Scaffolds for Peripheral Nerve Injury: The Involvement of miR-21-Notch Signaling Pathway
Current Neurovascular Research Factors that Control the Circulation Time of Nanoparticles in Blood: Challenges, Solutions and Future Prospects
Current Pharmaceutical Design Analgesic Drug Use Associated with Statin Prescription – A Cross- Sectional Study in Primary Care Settings
Current Drug Safety Outcomes in Older Versus Younger Patients Over 96 Weeks in HIV-1– Infected Patients Treated with Rilpivirine or Efavirenz in ECHO and THRIVE
Current HIV Research Neuroprotection by Estrogen and Progesterone in Traumatic Brain Injury and Spinal Cord Injury
Current Neuropharmacology Cycloxygenase-2 (COX-2) - A Potential Target for Screening of Small Molecules as Radiation Countermeasure Agents: An In Silico Study
Current Computer-Aided Drug Design Cellular Mechanisms of Striatum-Dependent Behavioral Plasticity and Drug Addiction
Current Molecular Medicine MicroRNAs and Peroxisome Proliferator-Activated Receptors Governing the Differentiation of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Gene Therapy for Neuroprotection and Neurorestoration (Part I)
Current Gene Therapy Nitric Oxide: Target for Therapeutic Strategies in Alzheimers Disease
Current Pharmaceutical Design Molecular Mechanisms of Thiamine Utilization.
Current Molecular Medicine The Palmitoylethanolamide Family: A New Class of Anti-Inflammatory Agents ?
Current Medicinal Chemistry Systems Genomics Support for Immune and Inflammation Hypothesis of Depression
Current Neuropharmacology